Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFSA 2025 Late-Breaking Science Collection
Author(s): Nir Uriel Added: 8 months ago
Discover the latest heart failure data from impactful trials and studies presented at the Heart Failure Society of America's annual congress, HFSA 2025.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators. View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
ADA 25: Efficacy and Safety of CagriSema in REDEFINE 1 and 2
Author(s): Sue Pedersen Added: 11 months ago
ADA 25 - CagriSema shows benefits in obesity and type 2 diabetes in the REDEFINE 1 and 2 trials.In this video, we are joined by Dr Sue Pedersen (C-endo Diabetes and Endocrinology Clinic, Calgary, CA) to discuss the findings from the REDEFINE 1 and 2 trials which investigated the effect of CagriSema 2.4mg.Findings showed that CagriSema was associated with weight reduction efficacy across patients… View more

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Director of the Obesity, Metabolism & Nutrition Institute
Dr Lee Kaplan is Director of the Obesity, Metabolism & Nutrition Institute, founding director of the Weight Center at the Massachusetts General Hospital, and associate professor of medicine at Harvard Medical School. Dr Kaplan's clinical expertise is in the areas of obesity medicine, gastroenterology and liver disease. The author of more than 150 medical and scientific papers, he has a special… View more
OMA Annual Conference 2025
Start date: Apr 23, 2025 End date: Apr 27, 2025
Event Dates: April 23–27, 2025Location: National Harbor, MarylandFocus: Obesity treatment, clinical practices, and patient care advancementsThe Obesity Medicine 2025 conference, hosted by the Obesity Medicine Association (OMA), is a vital opportunity for healthcare professionals dedicated to treating obesity. This annual event offers a comprehensive program featuring the latest research, clinical… View more
Research Area(s) / Expertise: Job title: Professor, Obesity and Stress Hormone Research
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center in Rotterdam, Netherlands. Sheis also co-founder of the Obesity Center CGG, an internationally recognised academic centre of obesity management.Prof Van Rossum holds various societal and board positions, amongst the European lead… View more
Maternal Cardiac Function in Pregnancies With Metabolic Disorders
Author(s): Deesha Patel , Makrina D Savvidou Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
HRS 25: The TRANSFORM-AF Study
Author(s): Varun Sundaram Added: 1 year ago
HRS 25 - TRANSFORM-AF shows patients with atrial fibrillation and obesity treated with a GLP-1 RA experienced a reduction in atrial fibrillation (AF)-related events.We are joined by Dr Varun Sundaram (Case Western Reserve University, US) to discuss the findings from the TRANSFORM-AF Study, which aimed to determine whether GLP-1 RAs could reduce the burden of AF in patients with both AF and… View more

Cardiovascular Kidney Metabolic

Electrophysiology & Arrhythmia
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie
Author(s): Harriette Van Spall , Mark Petrie Added: 2 years ago
HFA 2024 — Join experts, Dr Harriette Van Spall (McMaster University, CA) and Dr Mark Petrie (University of Glasgow, UK) for an insightful wrap up of the novel data presented at 2024's Heart Failure Congress.00:24 - STEP HFpEF Programme: Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF & Semaglutide therapy and diuretic use in obesity-related HFpEF02:20 - EMPACT-MI: The effect of… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Author(s): Barbara McGowan Added: 2 years ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic